Prostate Cancer Microparticles Expressing CD151 as a Predictive Biomarker for Progression to Metastasis

Abstract

We have found that the monoclonal antibody specific for a specific epitope of CD151 that is hypothesized to be expressed on prostate cancer microparticles from metastatic prostate cancer patients is also expressed on a subpopulation of prostate cancer microparticles from localized prostate cancer patients undergoing radical treatment. Therefore, a new direction is to analyze prostate cancer microparticles from patients on active surveillance (low risk PCa patients under watchful waiting) and we hypothesize that these patients will have the lowest percentage of 1A5-positive prostate microparticles. Those patients that do have high levels of 1A5-positive prostate microparticles will be followed to determine if their disease progresses and requires radical therapy (surgery, radiation).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2012
Accession Number
ADA574741

Entities

People

  • Hon Leong

Organizations

  • Western University

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biological Markers
  • Biomedical Research
  • Cancer
  • Cells
  • Data Analysis
  • Department Of Defense
  • Diseases And Disorders
  • Health Services
  • Medical Personnel
  • Metastasis
  • Neoplasms
  • Oncology
  • Prostate Cancer
  • Statistical Analysis
  • Surveillance
  • Tissues

Fields of Study

  • Biology

Readers

  • Industrial Economics
  • Prostate Cancer Biology.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.